Severe COVID-19 is characterized by the co-occurrence of moderate cytokine inflammation and severe monocyte dysregulation

• Published in: EBioMedicine 2021-11, Vol.73, p.103622-103622, Article 103622
• Main Authors: Bonnet, Benjamin, Cosme, Justine, Dupuis, Claire, Coupez, Elisabeth, Adda, Mireille, Calvet, Laure, Fabre, Laurie, Saint-Sardos, Pierre, Bereiziat, Marine, Vidal, Magali, Laurichesse, Henri, Souweine, Bertrand, Evrard, Bertrand
• Format: Article
• Language: English
• Subjects: Aged; COVID-19 - complications; COVID-19 - pathology; COVID-19 - virology; Cytokine Release Syndrome - etiology; Cytokines - blood; Female; HLA-DR; HLA-DR Antigens - metabolism; Humans; Immunosuppression; Inflammation; Intensive care unit; Intensive Care Units; Interleukin-6 - blood; Male; Middle Aged; Monocyte dysregulation; Monocytes - cytology; Monocytes - immunology; Monocytes - metabolism; Prospective Studies; Research Paper; SARS-CoV-2; SARS-CoV-2 - isolation & purification; Secondary infection; Severity of Illness Index
• ISSN: 2352-3964; 2352-3964
• DOI: 10.1016/j.ebiom.2021.103622

SARS-CoV-2 has been responsible for considerable mortality worldwide, owing in particular to pulmonary failures such as ARDS, but also to other visceral failures and secondary infections. Recent progress in the characterization of the immunological mechanisms that result in severe organ injury led to the emergence of two successive hypotheses simultaneously tested here: hyperinflammation with cytokine storm syndrome or dysregulation of protective immunity resulting in immunosuppression and unrestrained viral dissemination. In a prospective observational monocentric study of 134 patients, we analysed a panel of plasma inflammatory and anti-inflammatory cytokines and measured monocyte dysregulation via their membrane expression of HLA-DR. We first compared the results of patients with moderate forms hospitalized in an infectious disease unit with those of patients with severe forms hospitalized in an intensive care unit. In the latter group of patients, we then analysed the differences between the surviving and non-surviving groups and between the groups with or without secondary infections. Higher blood IL-6 levels, lower quantitative expression of HLA-DR on blood monocytes and higher IL-6/mHLA-DR ratios were statistically associated with the risk of severe forms of the disease and among the latter with death and the early onset of secondary infections. The unique immunological profile in patients with severe COVID-19 corresponds to a moderate cytokine inflammation associated with severe monocyte dysregulation. Individuals with major CSS were rare in our cohort of hospitalized patients, especially since the use of corticosteroids, but formed a very severe subgroup of the disease. None.